The provincial pharmacy database was used to identify patients who had a pathological confirmation of PDAC and received at least once cycle of palliative-intent chemotherapy.
The patient received six cycles of palliative chemotherapy, consisting of gemcitabine and cisplatin, which resulted in a partial response.
One patient received and benefited from gefitinib, and the other from erlotinib after repeated cycles of palliative chemotherapy and targeted therapy.
For those present with lung metastasis es) alone as the first failure, 4-6 cycles of palliative chemotherapy with DDP based regimen was administered.
There were no differences in age, stage at diagnosis, total number of cycles of palliative chemotherapy, incidence of visceral metastasis, and metastatic sites with the exception of liver among breast cancer subtypes.
Patients are eligible for the trial based on the inclusion and exclusion criteria presented in Tables 1 and 2. Three patients who are at the time point of screening not operable will be treated with re-directed T cells administered into the pleural effusion after completion of 3 cycles of palliative chemotherapy.
After the first three cycles of palliative chemotherapy with epirubicin 50 mg/m2 and oxaliplatin 130 mg/m2 intravenously every third week and continuous oral administration of capecitabine (Xeloda®) 625 mg/m2 twice daily (EOX), thoracic and abdominal CT scans showed reduction of lung, liver and lymph node metastases.
Correspondingly, the erbB2 protein was found heterogeneously expressed by immunohistochemical staining of the primary tumor of the gastroesophageal junction, while negative in liver and bone metastases, but after three initial cycles of palliative chemotherapy with epirubicin, oxaliplatin and capecetabine, the representative bone metastasis stained strongly positive for erbB2.
In this last case, sepsis-related death occurred 12 days following commencement of cycle 1 of palliative second-line chemotherapy.
